提醒

AbCellera Biologics Inc. (ABCL)

NasdaqGS: ABCL · 即時價格 · USD

9.31

-0.45 (-4.61%)

收盤時： Aug 11, 2026, 3:59 PM

-4.61% (1D)

買價	7.26
市值	2.86B
營收 (ttm)	66.17M
淨利（ttm）	-164.66M
貝塔	1.19
EPS (ttm)	-0.54
本益比（ttm）	n/a
正向 PE	-13.04
P/B (ttm)	3.19
P/S (ttm)	43.16
Earnings Date	Nov 5, 2026

賣價	11.66
成交量	874,351
20 日平均成交量	7,727,175
打開	9.25
上一頁關閉	9.76
日間範圍	9.15 - 9.51
52 週範圍	2.75 - 10.29
分析師	Strong Buy
目標價	15 (61.12%)
股利	n/a
Ex-股利日期	n/a

關於ABCL

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, su...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 Dec 11, 2020

員工 562

證券交易所 NasdaqGS

股票代號 ABCL

網站 https://www.abcellera.com

完整的公司簡介

財務表現

AbCellera Biologics 在 2025 年的營收為 75.13M，較前一年的 28.83M 增加 160.56%。淨利為 -146.41M，較前期減少 -10.1%。

財務報表

分析師預測

根據8 分析師評等，ABCL股票的平均評等為「Strong Buy」。 12個月股價預測為15，與最新價格相比為上漲空間的61.12%。

股票預測

獲利驚喜

AbCellera Biologics 已於 Aug 5, 2026 公布季度財報：

營收的 $4.05M 錯過估計 $0, 與 -76.29% YoY 下降.

EPS 的 -0.18 錯過估計 -0.02, 與 -50.00% YoY 下降.

下次財報發布

AbCellera Biologics Inc. 定於發布財報 Nov 5, 2026, 在市場交易時間內。
分析師預估營收 ... 升級

新聞動態

2 小時前 · Simply Wall St.

AbCellera Biologics (ABCL) Is Up 60.3% After Strong Phase 2 Menopause Data For ABCL635 - Has The Bull Case Changed?

AbCellera Biologics recently reported that its investigational antibody ABCL635 achieved statistically significant Phase 2 results, with a single 600 mg subcutaneous dose reducing both the frequency a...

3 小時前 · Simply Wall St.

AbCellera Biologics (ABCL) Stock Sees Fair Value Lift After Clinical Data And Jazz Deal

The latest analyst update on AbCellera Biologics reflects a higher Fair Value estimate of US$14.63 compared with the prior figure of US$10.43. This shift aligns with more constructive Street research ...

12 小時前 · Simply Wall St.

AbCellera Biologics (ABCL) Could Be 33% Overvalued Following ABCL635 Phase 2 Results

Why ABCL635’s Phase 2 data matters for AbCellera Biologics stock AbCellera Biologics (ABCL) has become a focus for many biotech investors after announcing that ABCL635 met primary endpoints in a Phase...

18 小時前 · Simply Wall St.

AbCellera Biologics (ABCL) Gets Its First Pipeline Win With Positive Phase 2 Data

AbCellera Biologics (NasdaqGS:ABCL) reports positive top line Phase 2 results for ABCL635, its non hormonal antibody treatment for moderate to severe menopausal vasomotor symptoms. The trial shows cli...

23 小時前 · Simply Wall St.

Is AbCellera Biologics (ABCL) Fully Valued After Its 172% Run?

AbCellera Biologics stock has surged year to date, yet the company scores poorly on broad valuation checks and currently screens as expensive on market multiples. After a strong run supported by posit...

第 1 頁，共 2 頁

AbCellera Biologics Inc. (ABCL)